Literature DB >> 24488418

Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Gulen Hatemi1, Peter A Merkel, Vedat Hamuryudan, Maarten Boers, Haner Direskeneli, Sibel Z Aydin, Hasan Yazici.   

Abstract

Behçet syndrome (BS) is a multisystem vasculitis that is most active during young adulthood, causing serious disability and significant impairment in quality of life. Differences in the disease course, severity, and organ involvement between patients, depending on the age at presentation and sex, makes it impossible to determine a single management strategy. The diversity and variability in the outcome measures used in clinical trials in BS makes it difficult to compare the results or inform physicians about the best management strategy for individual patients. There is a large unmet need to determine or develop validated outcome measures for use in clinical trials in BS that are acceptable to researchers and regulatory agencies. We conducted a systematic review to describe the outcomes and outcome measures that have been used in clinical trials in BS. This review revealed the diversity and variability in the outcomes and outcome measures and the lack of standard definitions for most outcomes and rarity of validated outcome tools for disease assessment in BS. This systematic literature review will identify domains and candidate instruments for use in a Delphi exercise, the next step in the development of a core set of outcome measures that are properly validated and widely accepted by the collaboration of researchers from many different regions of the world and from different specialties, including rheumatology, ophthalmology, dermatology, gastroenterology, and neurology.

Entities:  

Keywords:  ASSESSMENT; BEHÇET SYNDROME; OUTCOMES; SYSTEMATIC REVIEW

Mesh:

Year:  2014        PMID: 24488418      PMCID: PMC4508275          DOI: 10.3899/jrheum.131249

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  256 in total

1.  Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors:  G Akman-Demir; P Serdaroglu; B Tasçi
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

2.  The prevalence of fibromyalgia in patients with Behçet's disease and its relation with disease activity.

Authors:  Mehmet Melikoglu; Meltem Alkan Melikoglu
Journal:  Rheumatol Int       Date:  2012-09-28       Impact factor: 2.631

3.  Low dose cyclosporin-A therapy in Behçet's disease.

Authors:  H Sajjadi; M Soheilian; H Ahmadieh; K Hassanein; M Parvin; M Azarmina; V Ehyaee; B Amiransari
Journal:  J Ocul Pharmacol       Date:  1994

4.  Serum substance P and calcitonin gene-related peptide levels in Behçet's disease and their association with disease activity.

Authors:  T Aki; Y Karincaoglu; M Seyhan; K Batcioglu
Journal:  Clin Exp Dermatol       Date:  2006-07       Impact factor: 3.470

5.  Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial.

Authors:  Fereydoun Davatchi; Bahar Sadeghi Abdollahi; Arash Tehrani Banihashemi; Farhad Shahram; Abdolhadi Nadji; Hormoz Shams; Cheyda Chams-Davatchi
Journal:  Mod Rheumatol       Date:  2009-07-14       Impact factor: 3.023

6.  Clinical features and natural course of Behçet's disease in 661 cases: a multicentre study.

Authors:  E Alpsoy; L Donmez; M Onder; S Gunasti; A Usta; Y Karincaoglu; B Kandi; S Buyukkara; O Keseroglu; S Uzun; U Tursen; M Seyhan; A Akman
Journal:  Br J Dermatol       Date:  2007-08-17       Impact factor: 9.302

7.  Depression and anxiety in patients with Behçet's disease compared with that in patients with psoriasis.

Authors:  Ender Taner; Behcet Coşar; Sabri Burhanoğlu; Emel Calikoğlu; Meltem Onder; Zehra Arikan
Journal:  Int J Dermatol       Date:  2007-11       Impact factor: 2.736

8.  Oral health and related quality of life status in patients from UK and Turkey: a comparative study in Behcet's disease.

Authors:  G Mumcu; S Niazi; J Stewart; E Hagi-Pavli; B Gokani; N Seoudi; T Ergun; S Yavuz; M Stanford; F Fortune; H Direskeneli
Journal:  J Oral Pathol Med       Date:  2009-03-02       Impact factor: 4.253

9.  Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.

Authors:  Yukiko Yamada; Sunao Sugita; Hiroyuki Tanaka; Koju Kamoi; Tatsushi Kawaguchi; Manabu Mochizuki
Journal:  Br J Ophthalmol       Date:  2009-08-18       Impact factor: 4.638

10.  Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study.

Authors:  F Moral; V Hamuryudan; S Yurdakul; H Yazici
Journal:  Clin Exp Rheumatol       Date:  1995 Jul-Aug       Impact factor: 4.473

View more
  18 in total

Review 1.  Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014.

Authors:  Gulen Hatemi; Yesim Ozguler; Haner Direskeneli; Alfred Mahr; Ahmet Gul; Virna Levi; Sibel Z Aydin; Gonca Mumcu; Ozlem Sertel-Berk; Randall M Stevens; Hasan Yazici; Peter A Merkel
Journal:  J Rheumatol       Date:  2015-09-15       Impact factor: 4.666

2.  Evaluation of treatment adherence in patients with Behçet's disease: its relation to disease manifestations, patients' beliefs about medications, and quality of life.

Authors:  Hania S Zayed; Basma M Medhat; Esraa M Seif
Journal:  Clin Rheumatol       Date:  2018-10-26       Impact factor: 2.980

Review 3.  Interventions for the management of oral ulcers in Behçet's disease.

Authors:  Jennifer Taylor; Anne-Marie Glenny; Tanya Walsh; Paul Brocklehurst; Philip Riley; Rachel Gorodkin; Michael N Pemberton
Journal:  Cochrane Database Syst Rev       Date:  2014-09-25

4.  Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.

Authors:  Claudia Fabiani; Antonio Vitale; Giacomo Emmi; Lorenzo Vannozzi; Giuseppe Lopalco; Silvana Guerriero; Ida Orlando; Rossella Franceschini; Daniela Bacherini; Luca Cimino; Alessandra Soriano; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Carlo Salvarani; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2016-11-16       Impact factor: 2.980

Review 5.  Behçet syndrome: a contemporary view.

Authors:  Hasan Yazici; Emire Seyahi; Gulen Hatemi; Yusuf Yazici
Journal:  Nat Rev Rheumatol       Date:  2018-01-03       Impact factor: 20.543

Review 6.  Patient-reported outcomes in core domain sets for rheumatic diseases.

Authors:  Lilian H D van Tuyl; Maarten Boers
Journal:  Nat Rev Rheumatol       Date:  2015-09-01       Impact factor: 20.543

7.  Current status of outcome measure development in vasculitis.

Authors:  Peter A Merkel; Sibel Z Aydin; Maarten Boers; Christina Cornell; Haner Direskeneli; Don Gebhart; Gulen Hatemi; Raashid Luqmani; Eric L Matteson; Nataliya Milman; Joanna Robson; Philip Seo; Gunnar Tomasson
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

8.  Genital ulcer severity score and genital health quality of life in Behçet's disease.

Authors:  Amal Senusi; Noha Seoudi; Lesley Ann Bergmeier; Farida Fortune
Journal:  Orphanet J Rare Dis       Date:  2015-09-22       Impact factor: 4.123

9.  Does illness perception associate with disease symptoms in Behçet's disease?

Authors:  Gonca Mumcu; Fedayi Yağar; Fatma Alibaz-Öner; Nevsun İnanç; Haner Direskeneli; Tulin Ergun
Journal:  Intern Emerg Med       Date:  2018-11-30       Impact factor: 3.397

10.  Evaluation of diode laser versus topical corticosteroid in management of Behcet's disease-associated oral ulcers: a randomized clinical trial.

Authors:  Clair Sobhy Nagieb; Tarek Abd-ElHamid Harhash; Hala Lotfy Fayed; Shereen Ali
Journal:  Clin Oral Investig       Date:  2021-07-02       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.